Novartis AG ADR (NVS)vsSTAAR Surgical Company (STAA)
NVS
Novartis AG ADR
$160.32
-0.04%
HEALTHCARE · Cap: $303.67B
STAA
STAAR Surgical Company
$26.78
+0.34%
HEALTHCARE · Cap: $1.34B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 17375% more annual revenue ($57.36B vs $328.27M). NVS leads profitability with a 17.5% profit margin vs 0.2%. STAA appears more attractively valued with a PEG of 0.76. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
STAA
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.8%
Fair Value
$95.76
Current Price
$160.32
$64.56 premium
Margin of Safety
+50.0%
Fair Value
$34.47
Current Price
$26.78
$7.69 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 34.3%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
Grey zone — moderate risk
Smaller company, higher risk/reward
0.2% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : STAA
The strongest argument for STAA centers on Debt/Equity, PEG Ratio. PEG of 0.76 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : STAA
The primary concerns for STAA are Altman Z-Score, Market Cap, Profit Margin. A P/E of 2669.0x leaves little room for execution misses. Thin 0.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
STAA carries more volatility with a beta of 1.20 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (48/100 vs 36/100), backed by strong 17.5% margins. STAA offers better value entry with a 50.0% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →STAAR Surgical Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
STAAR Surgical Company designs, develops, manufactures, markets and sells implantable eye lenses and supplemental delivery systems for placing the lenses in the eye. The company is headquartered in Lake Forest, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?